ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting.
The study assessed anti-tumor activity in lung and breast cancer mouse models utilizing intratumoral administration of adenovirus (Ad) with the novel RheoSwitch Therapeutic System(R) (RTS(R)) technology, a DNA-based inducible promoter system, for regulated expression of murine IL-12 (mIL-12) or murine IFNα (mIFNα). Oral administration of a small molecule activator ligand (AL), INXN-1001, was used to regulate the expression of mIL-12 in Ad-RTS-mIL-12 and mIFNα in Ad-RTS-mIFNα.
In the lung cancer model, each therapy, combined with AL, was found to induce significant tumor growth inhibition by day 25 (72%, mIL-12, and 71%, mIFNα; p<0.05). Notably, combined treatment with Ad-RTS-mIL-12 and Ad-RTS-mIFNα with oral AL resulted in significantly enhanced anti-tumor effect compared to either treatment alone (96% growth inhibition; p<0.05) without overt toxicity as assessed by no change in body weight. In the breast cancer model, treatment led to 58% (mIL-12) and 53% (mIFNα) inhibition of tumor growth compared to control untreated tumors by day 34 (p<0.05). Again, concomitant treatment resulted in significantly enhanced anti-tumor activity with 80% growth inhibition.
"Current cancer immunotherapies have provided limited success in the clinic and innovative strategies are required to further enhance the effectiveness of an anti-tumor immune response," said Ronald B. Herberman, M.D., Chief Medical Officer -- Oncology of Intrexon Corporation. "Synthetic biology, specifically, the use of regulated gene systems, offers us the ability to tightly control the delivery of immune therapies in vivo in a way which optimizes benefit relative to risk. We have seen the benefit of this approach in a Phase 1 clinical trial using a regulated IL-12 gene expression, and now, in the promise of a combined therapy approach using a regulated combination of IL-12 and IFNα in preclinical models."
"These data indicate that a combined treatment strategy using RheoSwitch(R)-regulated IL-12 and IFNα induces effective therapeutic activity and minimal toxicity against aggressive murine tumors," said Hagop Youssoufian, M.Sc., M.D., President of Research and Development and Chief Medical Officer. "Using DNA to express these proteins in vivo and to control their expression with an oral activator is a novel approach with significant potential. Future preclinical studies will investigate the mechanism by which both IL-12 and IFNα exert their anti-tumor effect, an approach we hope to move into the clinic once validated."
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. The company's clinical programs include:
Palifosfamide (Zymafos(R) or ZIO-201) is a novel DNA cross-linker that in preclinical study has been shown to bypass resistance mediated by aldehyde dehydrogenase (ALDH), in addition to conferring a favorable toxicity profile compared to other in-class agents. Palifosfamide, administered intravenously, is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. A Phase 1 trial is also nearing completion with palifosfamide in combination with etoposide and carboplatin to determine appropriate safety for initiating a potentially pivotal, adaptive Phase 3 trial in front-line, extensive SCLC expected to initiate in the second half of 2012. Additionally, an investigational new drug application has been accepted for the oral form of palifosfamide.
DNA-based therapeutics (synthetic biology), in partnership with Intrexon Corporation, include two clinical-stage product candidates, both of which are DNA IL-12 using the RheoSwitch Therapeutic System(R) to be turned on/off by an oral activator ligand and are currently in Phase 1. Additionally, multiple INDs are expected in the next 12-24 months resulting from preclinical and discovery work underway to advance multiple antibody, immunotoxin, and protein decoy candidates, systemic delivery and a next generation RheoSwitch Therapeutic System(R).
Indibulin (Zybulin(TM) or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase 1/2 in metastatic breast cancer.
Darinaparsin (Zinapar(R) or ZIO-101) is a novel mitochondrial- and hedgehog-targeted agent (organic arsenic) currently in a solid tumor Phase 1 study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma.
ZIOPHARM's operations are located in Boston, MA, Germantown, MD and New York City.
For more information, visit http://www.ziopharm.com or call 6617/778-2266.
|Printer friendly Cite/link Email Feedback|
|Date:||May 1, 2012|
|Previous Article:||Raptor Pharmaceutical Submits NDA for RP103.|
|Next Article:||Immunomedics Radioimmunotherapy of Colorectal Cancer.|